Quality improvement in acute stroke: The New York State Stroke Center Designation Project

Neurology

Volumn 67, Issue 1, 2006, Pages 88-93

  Gropen, T I ^a   Gagliano, P J ^b   Blake, C A ^c   Sacco, R L ^d   Kwiatkowski, T ^e   Richmond, N J ⁱ   Leifer, D ^f,g   Libman, R ^e   Azhar, S ^h   Daley, M B ^b  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^h LUTHERAN MEDICAL CENTER   (United States)

ⁱ Louisville Metro EMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; FEMALE; HEALTH CARE QUALITY; HEALTH CENTER; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STROKE; UNITED STATES; AGED; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; HOSPITAL DEPARTMENT; MULTICENTER STUDY; OUTCOME ASSESSMENT; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; STATISTICS; TIME;

AGED; CEREBROVASCULAR ACCIDENT; DEMOGRAPHY; FEMALE; GUIDELINE ADHERENCE; HOSPITAL DEPARTMENTS; HUMANS; MALE; NEW YORK; OUTCOME ASSESSMENT (HEALTH CARE); PLASMINOGEN ACTIVATORS; PUBLIC HEALTH ADMINISTRATION; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33746818779     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000223622.13641.6d     Document Type: Article

References (22)

1. Schwamm LH, Pancioli A, Acker JE, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Stroke 2005;36:690-703.
2. Alberts MJ, Hademenos G, Latchaw RF, et al. Recommendations for the establishment of primary stroke centers. JAMA 2000;283:3102-3109.
3. Kothari RU, Pancioli A, Liu T, Brott T, Broderick J. Cincinnati prehospital stroke scale: reproducibility and validity. Ann Emerg Med 1999;33:373-378.
4. Douglas VC, Tong DC, Gillum LA, et al. Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke? Neurology 2005;64:422-427.
5. Wojner-Alexandrov AW, Alexandrov AV, Rodriguez D, Persse D, Grotta JC. Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO). Stroke 2005;36:1512-1518.
6. The National Institute of Neurologic Disorders and the Stoke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
7. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997;314:1151-1159.
8. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-1158.
9. Scott PA, Smith RW, Chudnofsky CR, et al. Emergency physician administration of rt-PA therapy in acute stroke: analysis of treatment and outcome. Stroke 1999;30:244.
10. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001;32:12-16.
11. Katzan IL, Hammer MD, Furlan AJ, et al. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003;34:799-800.
12. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
13. Grond M, Stenzel C, Schmülling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-1549.
14. Tanne D, Bates VE, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 1999;53:424-427.
15. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000;283:1145-1150.
16. Goldstein LB, Hey LA, Laney R. North Carolina stroke prevention and treatment facilities survey: statewide availability of programs and services. Stroke 2000;31:66-70.
17. Kidwell CS, Shephard T, Tonn S, et al. Establishment of primary stroke centers: a survey of physician attitudes and hospital resources. Neurology 2003;60:1452-1456.
18. Adams HP, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056-1083.
19. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004;35:e27-e29.
20. Streifler JY, Davidovitch S, Sendovski U. Factors associated with the time of presentation of acute stroke patients in an Israeli community hospital. Neuroepidemiology 1998;17:161-166.
21. Goldstein LB, Edwards MG, Wood DP. Delay between stroke onset and emergency department evaluation. Neuroepidemiology 2001;20:196-200.
22. Joint Commission on Accreditation of Healthcare Organizations. Primary Stroke Centers. Available at: http://www.jcaho.org/dscc/psc/index.htm; accessed January 3, 2006.